Glatt Pharmaceutical Services and Aprecia have teamed up to accelerate and expand the use of Glatt's multiparticulate technologies through Aprecia's 3DP manufacturing. This effort will focus on overcoming oral pharmaceutical design challenges presented by conventional manufacturing. Leveraging Aprecia's ZipDose technology, the collaboration will initially target existing products for modified release 505(b)(2) brand line extensions as well as new chemical entities (NCE) through accelerated clinical development and patient focused dosage forms.
Glatt Pharmaceutical Services and Aprecia announced on Feb. 23, 2021 a joint effort to accelerate and expand the use of Glatt's multiparticulate technologies through Aprecia's ZipDose technology for 3DP manufacturing. The collaboration will advance manufacturing solutions for oral pharmaceutical design challenges that are not addressed by conventional oral solid-dosage manufacturing. The collaboration will initially target existing products for modified release brand-line extensions as well as new chemical entities through accelerated clinical development and patient-focused dosage forms.
The Pharmaceutical Equipment market report that is recently published by Market Expertz is inclusive of all key players, current market scenario, regions that the market functions, strategies employed by the influential participants and applications of the products of this market. The report is examined using data that is obtained from reliable resources and industry experts, to maintain the accuracy, giving implementable strategies and options to the users of the report. The influential players of the Pharmaceutical Equipment industry are mentioned and highlighted with relevant and updated facts. Also, the strategies applied by these participants are explained vividly.
The pharmaceutical continuous manufacturing market is expected to reach US$ 3,064.38 million by 2027 from US$ 1,459.53 million in 2019. The market is estimated to grow at a CAGR of 9.8% from 2020 to 2027. The growth of the market is attributed to key driving factors such as increasing shortage of medicines and advantages offered by continuous manufacturing process. However, high capital costs required for the establishment of these systems expected to restrain the growth of the market during the forecast period.
The latest market intelligence study on Pharmaceutical Continuous Manufacturing relies on the statistics derived from both primary and secondary research to present insights pertaining to the forecasting model, opportunities, and competitive landscape of Pharmaceutical Continuous Manufacturing market for the forecast period 2020-2025.
The Granulators for Pharmaceutical market has been garnering remarkable momentum in recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the market. Report Hive’s latest publication, Titled “[Granulators for Pharmaceutical Market Research Report 2020]”, offers an insightful take on the drivers and restraints present in the market. This is the latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. It assesses the historical data pertaining to the Granulators for Pharmaceutical market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market.
An innovative medicine enabling nanotechnology company, has won the Excellence in Pharma Award for Formulation at the prestigious CPhI Pharma Awards.
Improved performance for crop protection products
Finnish biotech Nanoform has taken home the Excellence in Pharma Award for Formulation at this year's CPhI Pharma Awards. Receiving this highly contested prize is an acknowledgement of Nanoform’s commitment to innovation in the industry through its best-in-class Controlled Expansion of Supercritical Solutions nanonisation technology.